Biodrugs

Papers
(The H4-Index of Biodrugs is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry286
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond204
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis98
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome96
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making82
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy74
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis72
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery60
Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design59
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor57
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart48
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic46
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–202242
Acknowledgement to Referees40
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials36
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?33
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies33
CAR-T Cells and the Kidney: Insights from the WHO Safety Database32
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?31
Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy31
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review30
The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis30
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data28
Progress and Challenges in the Treatment of Fabry Disease27
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer27
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase27
Malaria Vaccines: Progress to Date27
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?27
0.028579950332642